Research Center for Vitamins and Vaccines (CVIVA), Bandim Health Project, Statens Serum Institut, Copenhagen, Denmark.
Section of Epidemiology, Department of Public Health, The University of Copenhagen, Copenhagen, Denmark.
Int J Epidemiol. 2019 Dec 1;48(6):2026-2038. doi: 10.1093/ije/dyz062.
Live vaccines may have beneficial non-specific effects. We tested whether the live measles, mumps and rubella (MMR) vaccine compared with the non-live diphtheria-tetanus-acellular-pertussis-inactivated-polio-Haemophilus influenzae type b (DTaP-IPV-Hib) vaccine as the most recent vaccine was associated with less childhood asthma and fewer acute hospital contacts for childhood asthma among boys and girls.
This study is a nationwide register-based cohort study of 338 761 Danish children born between 1999 and 2006. We compared (i) the incidence of first-registered childhood asthma based on hospital contacts and drug prescriptions and (ii) the incidence of severe asthma defined as acute hospital contacts for childhood asthma between the ages of 15 and 48 months among children whose last received vaccine was three doses of DTaP-IPV-Hib and then MMR with children whose last received vaccine was three doses of DTaP-IPV-Hib.
For boys, following the recommended vaccine schedule of MMR after DTaP-IPV-Hib3 compared with DTaP-IPV-Hib3 as the last received vaccine, MMR was associated with 8.1 (95% confidence interval 3.9-12.3) fewer childhood asthma cases per 1000 boys, corresponding to 10% (5-15%) reduction in the cumulative incidence of childhood asthma. MMR, when given last, was also associated with 16.3 (95% confidence interval 12.7-20.0) fewer acute hospital admissions for childhood asthma per 1000 boys, corresponding to a 27% (22-31%) reduction in the cumulative incidence. No associations were seen for girls.
MMR may have a protective effect against childhood asthma for boys. This calls for an understanding of whether non-specific effects of vaccines can be used to optimize our vaccine programmes.
活疫苗可能具有有益的非特异性作用。我们检测了麻疹、腮腺炎和风疹(MMR)活疫苗与非活白喉-破伤风-无细胞百日咳-灭活脊髓灰质炎-乙型流感嗜血杆菌(DTaP-IPV-Hib)疫苗相比,作为最近接种的疫苗,是否与男童和女童的儿童哮喘减少和儿童哮喘急性住院次数减少相关。
本研究是一项基于丹麦全国登记的队列研究,共纳入 338761 名 1999 年至 2006 年出生的儿童。我们比较了(i)根据医院就诊和药物处方首次登记的儿童哮喘发病率和(ii)15 至 48 月龄儿童中严重哮喘的发病率,严重哮喘定义为儿童哮喘急性住院。这些儿童的最后一剂疫苗为三剂 DTaP-IPV-Hib,随后接种三剂 MMR,与最后一剂疫苗为三剂 DTaP-IPV-Hib 的儿童相比。
对于男孩,与最后一剂疫苗为 DTaP-IPV-Hib3 相比,按照 MMR 推荐的疫苗接种方案,在 DTaP-IPV-Hib3 后接种 MMR,每 1000 名男孩中发生的儿童哮喘病例减少 8.1(95%置信区间 3.9-12.3),儿童哮喘的累积发病率降低 10%(5-15%)。最后一剂疫苗接种 MMR 也与每 1000 名男孩中儿童哮喘急性住院人数减少 16.3(95%置信区间 12.7-20.0)相关,儿童哮喘的累积发病率降低 27%(22-31%)。对于女孩,没有观察到相关性。
MMR 可能对男孩的儿童哮喘有保护作用。这需要我们了解疫苗的非特异性作用是否可以被用来优化我们的疫苗接种计划。